Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HOOK 
Hookipa Pharma Inc (HOOK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: HOOK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -9.01% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 10.25M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 3 | Beta 0.92 | 52 Weeks Range 0.72 - 5.66 | Updated Date 08/15/2025 |
52 Weeks Range 0.72 - 5.66 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.85 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -885.28% |
Management Effectiveness
Return on Assets (TTM) -45.2% | Return on Equity (TTM) -105.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -29542989 | Price to Sales(TTM) 1.1 |
Enterprise Value -29542989 | Price to Sales(TTM) 1.1 | ||
Enterprise Value to Revenue 1.91 | Enterprise Value to EBITDA 0.46 | Shares Outstanding 9799050 | Shares Floating 9622386 |
Shares Outstanding 9799050 | Shares Floating 9622386 | ||
Percent Insiders 19.27 | Percent Institutions 33.67 |
Upturn AI SWOT
Hookipa Pharma Inc
Company Overview
History and Background
Hookipa Pharma Inc. was founded in 2011. It is a biopharmaceutical company developing immunotherapies based on its proprietary arenavirus platform. Key milestones include developing preclinical and clinical candidates targeting infectious diseases and cancers.
Core Business Areas
- VaxWave Platform: VaxWave is Hookipa's replicating arenavirus vector platform for inducing strong T cell and antibody responses to fight infectious diseases and cancers.
- TheraT Platform: TheraT is Hookipa's non-replicating arenavirus vector platform. It is designed for cancer immunotherapy to boost anti-tumor immunity.
Leadership and Structure
Ignacio Pujol serves as the Chief Executive Officer. The company operates with a typical biotechnology organizational structure, focusing on research, development, and clinical trials.
Top Products and Market Share
Key Offerings
- HB-101 (CMV):: An investigational immunotherapeutic targeting cytomegalovirus (CMV) for transplant patients. It is in clinical development. Market share data is not yet available due to its developmental stage. Competitors in the CMV therapy space include companies developing antiviral drugs and vaccines like Moderna (MRNA).
- HB-700 (KRAS):: An investigational immunotherapeutic targeting KRAS-mutated cancers. It is in clinical development. Market share data is not yet available due to its developmental stage. Competitors in KRAS targeted therapies include companies developing small molecule inhibitors and other immunotherapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and strong competition. Immunotherapy is a growing field with significant potential for treating various diseases.
Positioning
Hookipa Pharma Inc. is positioned as a specialized player focusing on arenavirus-based immunotherapies. Its competitive advantage lies in its proprietary platform technologies. It aims to improve effectiveness and tolerability over existing treatments.
Total Addressable Market (TAM)
The TAM for cancer and infectious disease immunotherapies is estimated to be in the tens of billions of dollars. Hookipa is targeting niche segments within this large market with its specific platform technologies and product candidates.
Upturn SWOT Analysis
Strengths
- Proprietary arenavirus vector platforms
- Strong preclinical and clinical data for lead candidates
- Experienced management team
- Novel approach to immunotherapy
Weaknesses
- Limited financial resources
- Reliance on clinical trial success
- Small market capitalization
- Competition from larger pharmaceutical companies
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with new therapeutic targets
- Positive clinical trial results
- Market growth in immunotherapy
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other immunotherapies
- Patent challenges
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- GILD
Competitive Landscape
Hookipa Pharma Inc. competes with larger, more established pharmaceutical companies in the immunotherapy space. Its advantage lies in its proprietary platform, but it faces challenges in terms of resources and market reach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited, typical of an early-stage biotech company focused on R&D.
Future Projections: Future growth is dependent on successful clinical trial outcomes and potential commercialization or partnerships. Analyst estimates vary widely depending on the perceived potential of the company's pipeline.
Recent Initiatives: Recent initiatives include advancing clinical trials for lead candidates and seeking partnerships to expand development and commercialization efforts.
Summary
Hookipa Pharma Inc. is a small, early-stage biopharmaceutical company with a promising arenavirus-based immunotherapy platform. Its success is highly dependent on the outcome of its clinical trials. The company faces competition from larger, more established players and needs to secure partnerships or raise additional capital to continue its development programs. Positive clinical data is crucial for stock performance.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be made after consulting with a qualified financial advisor. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hookipa Pharma Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2019-04-18 | CEO, President & Director Dr. Malte Peters M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 82 | Website https://www.hookipapharma.com |
Full time employees 82 | Website https://www.hookipapharma.com | ||
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunetherapeutics targeting infectious diseases based on its proprietary arenavirus platform. The company's immuno-oncology pipeline includes HB-700, a novel next-generation multi-KRAS mutant-targeting investigational immunotherapy for the treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers; Eseba-vec, an investigational immunotherapeutic agent in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers with enrollment completed in a Phase 1/2 clinical trial; and HB-300, which targets self-antigens for the treatment of prostate cancer. It is also developing HB-400 for the treatment of Hepatitis B that is in Phase I of clinical trial; and HB-500 for the treatment of Human Immunodeficiency Virus (HIV) that is in Phase I of clinical trial. The company has a collaboration and license agreement with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products for the treatment, cure, diagnosis, or prevention of the hepatitis B virus (HBV) and the HIV. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.